Exhibit 99.24

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investor Presentation and Webinar

Melbourne, Australia, 28 July 2021: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a diversified Genomics and AI driven preventative health business provides the attached presentation and advises that the Company will be providing the following webinar for investors in Australia.

Thursday 29 July 2021 at 9:30am AEST/Wednesday 28 July at 7:30pm EST

To register please click on the link below.

https://us02web.zoom.us/webinar/register/WN_ntdVwrJPQkeM0XszdzUvXQ

-END-

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
info@gtglabs.com	Australia
ABN 17 009 212 328	+61 3 8412 7000

Investor Relations (AUS) Investor Relations and Media (US)

Stephanie Ottens Dave Gentry

Market Eye 1 800 RED CHIP (733 2447)

M: +61 434 405 400 Cell: 407 491 4498

E: stephanie.ottens@marketeye.com.au E: dave@redchip.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
info@gtglabs.com	Australia
ABN 17 009 212 328	+61 3 8412 7000